Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Hinderer
Karl Hinderer, Fichtenberg DE
| Patent application number | Description | Published |
|---|---|---|
| 20090001644 | Relocating Device Having at Least One Pilot Pin - A relocating device for a flexible processing line is embodied for relocating a workpiece holder ( | 01-01-2009 |
| 20090010739 | Processing Station for a Processing Line having a Module Platform and Withdrawable Modules that can be Introduced into the Module Platform - A processing station for a processing line, having a module platform ( | 01-08-2009 |
Mario Hinderer, Fichtenberg Ot Langert DE
| Patent application number | Description | Published |
|---|---|---|
| 20110068570 | CLAMPING COMPONENT COMPRISING A CUTTING ELEMENT FOR ESTABLISHING AN ELECTRICALLY CONDUCTIVE CONNECTION - A clamping component composed of metal and used to clamp a profiled element composed of metal has at least one clamping surface adapted to the profiled element, at least one cutting element which includes a cutting edge that extends beyond the clamping surface, thereby enabling the cutting element to penetrate the profiled element when the clamping component clamps the profiled element; and an engagement element for introducing a clamping force, wherein the cutting edge is situated at a slant and/or curve relative to the clamping surface such that the cutting edge initially touches the profiled element in a punctiform manner while the clamping part is clamped tightly, and an increasing region of the cutting edge subsequently penetrates the profiled element. | 03-24-2011 |
Robert Hinderer, Flint, MI US
| Patent application number | Description | Published |
|---|---|---|
| 20100330587 | Annexin Proteins and Autoantibodies As Serum Markers For Cancer - The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods. Such kits can be used to screen subjects for increased levels of annexin proteins, or for the detection of autoantibodies to annexin proteins, as a diagnostic, predictive or prognostic indicator of cancer. | 12-30-2010 |
Walter Hinderer, Rodgau DE
| Patent application number | Description | Published |
|---|---|---|
| 20090143292 | Liquid Formulation of G-CSF Conjugate - The present invention relates to a liquid pharmaceutical composition comprising a granulocyte colony stimulating factor polypeptide conjugated with a polymer. In various embodiments, the composition has a pH value in the range of 4.5 to 5.5. Exemplary compositions further comprise a surfactant and optionally one or more other pharmaceutically acceptable excipients. The invention provides, inter alia, formulations free from tartaric acid or salts thereof and/or from succinic acid and salts thereof as buffering agents. Exemplary formulations are essentially devoid of not amino acids as stabilizers. The composition has good storage stability and is especially useful for the prophylaxis and treatment of disorders and medical indications where granulocyte colony stimulating factor preparations are considered as useful remedies. | 06-04-2009 |
| 20110053844 | LIQUID FORMULATION OF G-CSF CONJUGATE - The present invention relates to a liquid pharmaceutical composition comprising a granulocyte colony stimulating factor polypeptide conjugated with a polymer, the composition having a pH value in the range of 4.5 to 5.5. The composition further comprises a surfactant and optionally one or more other pharmaceutically acceptable excipients. Further, the composition of the invention is free from tartaric acid or salts thereof and from succinic acid and salts thereof as buffering agents and does not contain amino acids as stabilizer. The composition has a good storage stability and is especially useful for the prophylaxis and treatment of disorders and medical indications where granulocyte colony stimulating factor preparations are considered as useful remedies. | 03-03-2011 |
Walter Hinderer, Rogau DE
| Patent application number | Description | Published |
|---|---|---|
| 20100216698 | LIQUID FORMULATIONS OF G-CSF - Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits. | 08-26-2010 |